De Novo Kaposi Sarcoma in an HIV-Negative Liver Transplant Recipient With Ulcerative Colitis and Primary Sclerosing Cholangitis

Pavithra Ramakrishnan; Khalid Amin; Wolfgang Gaertner; Elizabeth S Aby

doi:10.1155/crit/4699128

De Novo Kaposi Sarcoma in an HIV-Negative Liver Transplant Recipient With Ulcerative Colitis and Primary Sclerosing Cholangitis

Case Rep Transplant. 2024 Nov 12:2024:4699128. doi: 10.1155/crit/4699128. eCollection 2024.

Authors

Pavithra Ramakrishnan¹, Khalid Amin², Wolfgang Gaertner³, Elizabeth S Aby⁴

Affiliations

¹ Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
² Department of Pathology, University of Minnesota, Minneapolis, Minnesota, USA.
³ Division of Colon and Rectal Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
⁴ Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA.

Abstract

De novo or viral reactivation cancers are a major cause of morbidity and mortality in the solid organ transplant (SOT) population. Primary sclerosing cholangitis (PSC) is an aggressive disease which can lead to cholestatic liver damage and cirrhosis. PSC often cooccurs with inflammatory bowel disease (IBD). Here, we describe the case of a 28-year-old male with PSC along with poorly controlled IBD who underwent a liver transplant and developed colonic Kaposi sarcoma (KS). Our case highlights the importance of adequate pretransplant screening for endemic viruses, high clinical suspicion for KS in the setting of difficult-to-control colitis, and early multidisciplinary involvement.

Keywords: IBD; Kaposi sarcoma; liver transplant; ulcerative colitis; vedolizumab.

Publication types

Case Reports